The Department of Ophthalmology supports innovative basic science and clinical research aimed towards developing therapies for ocular diseases and conditions.
Rob Lin, PhD, CEO, Avista Therapeutics, says scAAVenger platform provides a cell-specific toolkit for gene therapy development, resulting in higher expression and lower inflammation with lower gene therapy doses. Avista management includes Sahel, Sieving, Byrne.
Si Chen, Kira Lathrop, Takaaki Kuwajima and Jeffrey Gross dissect the role of Jak/Stat signalling in modulating crosstalk between macrophages/microglia and retinal ganglion cells to regulate RGC survival after severe optic nerve injury
https://t.co/pnDud8CDyy
New!! The St. Leger Lab shows that VEGF-A immune cells disrupts corneal nerves leading to blinding disease during HSV-1 infection. @Immunity Check it out:https://t.co/zET1wVshWG
Postdoctoral Fellow in the epigenetic regulation of retinal development
NIH-funded postdoctoral position is available in the laboratory of Dr. Jeff Gross (https://t.co/AIx9FXadRf) in the Department of Ophthalmology at Pitt
Interested candidates send info to [email protected]
New work from the Byrne Lab just posted on bioRxiv! scAAVengr: Single-cell transcriptome-based quantification of engineered AAVs in non-human primate retina: https://t.co/PWvaW6VxeZ
@ByrneLabScience
Happy 60th Anniversary to @RPB_org and their President, Dr. Brian Hofland
Consider making an anniversary donation to the RPB via the attached link:
https://t.co/5BPKokeLXL
UPMC physicians first to implant next regeneration wireless retinal device in clinical trial to restore partial sight to patients with advanced age-related macular degeneration, which leads to permanent blindness and has no cure. https://t.co/CHExyrU5gw